Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients (Open-label Extension)
jRCT2031260200Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Open-label, single-arm trial of QCZ484 in hypertension (HTN), sponsored by Novartis. Primary endpoint: Number of participants with adverse events. Started Jun 2026; status: recruiting.
02
Drugs
QCZ484
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2031260200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260200.